Get notified when retatrutide reaches Canada

Join the waitlist for updates on Health Canada approval, clinical trial openings near you, and legitimate access pathways as they develop. No spam — only meaningful milestones.

What you'll receive

Approval milestones: When Eli Lilly files with Health Canada, when review begins, and when a decision is announced
Clinical trial openings: New Canadian trial sites as they begin recruiting
Data releases: Summaries of TRIUMPH Phase 3 results with Canadian context
Access updates: Changes to Health Canada Special Access Programme, provincial coverage decisions, pharmacy availability

We send at most 2–4 emails per month — only when there is meaningful news. You can unsubscribe at any time.

Your privacy: Your email is stored securely and used only for retatrutide availability updates. We never share, sell, or use your information for any other purpose.

Why a waitlist?

Retatrutide is moving through clinical trials, and the timeline to Canadian approval is uncertain. When Health Canada approval happens, demand will likely exceed supply — the same pattern seen with tirzepatide (Mounjaro) and semaglutide (Wegovy) in Canada.

Being on this list means you'll know about:

Trial sites opening near you — the earliest access pathway
Health Canada decision dates — before mainstream media coverage
Provincial coverage and private insurance updates
Compounding and safety warnings — to help you avoid unregulated products

We do not sell retatrutide, facilitate purchases, or provide medical advice. This waitlist is an educational alert service for Canadians tracking this drug's path to market.

Medical Disclaimer: This waitlist provides educational updates only. Joining does not create a doctor-patient relationship, guarantee access to any medication, or constitute a prescription. Retatrutide is not yet approved by Health Canada. Always consult a licensed healthcare provider.